Repligen RGEN 深 滬
等待開盤 09-11 09:30:00 美东时间
120.23
+1.540
+1.30%
華盛通- 最 高122.695
- 今 開118.40
- 成交量 98.65万股
- 最 低 117.5475
- 昨 收 118.69
- 總市值 67.64亿
- 52周最高 182.52
- 市盈率 靜 --
- 換手率 1.75%
- 52周最低 102.965
- 委 比 -94.12%
- 總股本 5625.76万
- 歷史最高 327.32
- 量 比 1.28
- 振 幅 4.34%
- 歷史最低 2.90
- 每 手 1
- 風險率 23.11%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多HC Wainwright & Co. Reiterates Buy on Repligen, Maintains $180 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Repligen (NASDAQ:RGEN) with a Buy and maintains $180 price target.
09-03 18:49
Recursion to Participate in Upcoming Investor Conferences
Re: Recursion's Participation in Upcoming Investor Conferences Recursion (NASDAQ: RXRX), a clinical stage TechBio company, announced its participation in the following investor conferences: - Citi 2025 BioPharma Back to School Conference – September 3, 2025 - Morgan Stanley 23rd Annual Global Healthcare Conference – September 8, 2025 Webcasts will be available on the Recursion Investor Relations website (ir.recursion.com). Recursion leverage...
08-27 12:00
Repligen Corporation to Present at Upcoming September Conferences
Repligen Corporation will attend three investor conferences in September 2025. Olivier Loeillot, CEO, will participate in discussions at the Wells Fargo Healthcare Conference on September 4 in Boston and at the Bank of America Global Healthcare Conference on September 25 in London. Jason Garland, CFO, will attend 1x1 meetings at the Deutsche Bank Healthcare Summit on September 10 in New York. Live webcasts will be available via Repligen’s Investo...
08-22 11:30
Repligen Stock Outlook: Risk Skewed To The Downside Through 2026
Repligen stock has been in a prolonged downtrend, and Adhishthana principles suggest more weakness ahead. Here's what investors should track...
07-31 22:45
Repligen Announces Strategic Partnership with Novasign to Further Advance Bioprocessing Digitalization
Repligen Corporation and Novasign have formed a strategic partnership to integrate Novasign's machine learning and modeling workflows into Repligen's tangential flow filtration (TFF) systems. The collaboration aims to enhance Repligen's digitalization efforts, improve process analytical technology (PAT)-enabled systems, and enable real-time predictive control, reducing development timelines and costs through digital twins. Novasign's expertise in...
07-31 11:30
Wells Fargo Maintains Overweight on Repligen, Lowers Price Target to $175
Wells Fargo analyst Brandon Couillard maintains Repligen (NASDAQ:RGEN) with a Overweight and lowers the price target from $180 to $175.
07-30 22:11
Repligen Raises FY2025 Adj EPS Guidance from $1.63-$1.72 to $1.65-$1.72 vs $1.68 Est; Raises FY2025 Sales Guidance from $695.000M-$720.000M to $715.000M-$735.000M vs $709.438M Est
Repligen (NASDAQ:RGEN) raises FY2025 Adj EPS guidance from $1.63-$1.72 to $1.65-$1.72 vs $1.68 analyst estimate. Raises FY2025 sales outlook from $695.000 million-$720.000 million to $715.000 million-$735.000 million vs
07-29 19:33
Repligen Q2 Adj. EPS $0.37 Misses $0.39 Estimate, Sales $182.000M Beat $174.831M Estimate
Repligen (NASDAQ:RGEN) reported quarterly earnings of $0.37 per share which missed the analyst consensus estimate of $0.39 by 5.85 percent. This is a 12.12 percent increase over earnings of $0.33 per share from the same
07-29 19:33
Earnings Scheduled For July 29, 2025
Companies Reporting Before The Bell • Barclays (NYSE:BCS) is projected to repor...
07-29 16:32
